• Clinical development


IO Biotech has an advanced pipeline with three compounds in phase I or I/II and several compounds in pre-clinical development

  • IO102: an anti-cancer therapy containing IDO-derived peptide. Clinically validated in cancer (NSCLC and Melanoma). A phase II program in NSCLC with IO102 in combination with an anti-PD-1 antibody is plan to be initiated in Q1, 2018.
  • IO103: an anti-cancer therapy containing PD-L1-derived peptide: Currently IO103 is in phase I/II for melanoma and in two phase I for Myeloma and Follicular Lymphoma.
  • IO130: an anti-cancer therapy containing TDO-derived peptide.
Target for IO112 and IO140 is to be announced soon.

Additional targets are under pre-clinical evaluation.

IO Biotech has entered into a clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer. IO Biotech will maintain global commercial rights to IO102.